Testosterone by Telehealth: Schedule III Rules and State Limits

Clinics that sell testosterone therapy online sometimes talk about it as a wellness product. Federal law does not. Anabolic steroids, including testosterone and its esters, are Schedule III controlled substances under 21 CFR 1308.13(f), a listing that dates to the Anabolic Steroid Control Act of 1990. Every telehealth testosterone prescription is a controlled substance prescription, which means the Ryan Haight Act, DEA registration, PDMP rules and state telehealth prescribing limits all apply.

What federal rules apply to a Schedule III prescription?

• A DEA registration covering Schedule III in the state where the patient is located, held by the prescriber, not the company.
• Refill limits. Under 21 CFR 1306.22(a), a Schedule III or IV prescription may not be filled or refilled more than six months after it was issued, or refilled more than five times. A twelve-month standing order is not possible; plan a new prescription at least every six months.
• Legitimate medical purpose. 21 CFR 1306.04(a) makes the prescriber responsible for issuing the prescription in the usual course of professional practice. Protocols that prescribe to anyone who pays, without labs or an evaluation that supports a diagnosis, are the weak point regulators look for.
• The in-person rule at 21 U.S.C. 829(e), which applies unless a telemedicine exception in 21 U.S.C. 802(54) does. See the Ryan Haight Act and its exceptions.

Can testosterone be prescribed by telehealth without an in-person visit today?

Through December 31, 2026, yes, under federal law. DEA and HHS's fourth temporary extension (90 FR 61301, codified at 21 CFR 1307.41) lets DEA-registered practitioners prescribe Schedule II through V drugs after a telemedicine encounter without a prior in-person evaluation. The encounter must use an interactive telecommunications system under 42 CFR 410.78(a)(3), which is real-time audio and video; audio-only qualifies only for a patient at home who cannot use video or does not consent to it.

From January 1, 2027, the answer depends on whether DEA has finalized its special registration rule, extended the temporary rule again, or neither. If neither, each testosterone patient needs an in-person evaluation by the prescriber, or another 802(54) pathway, before the next prescription. See what changes on January 1, 2027. The buprenorphine rule at 21 CFR 1306.51 is limited to opioid use disorder and does not help here.

What would the special registration proposal mean for testosterone?

Testosterone falls in the easier tier. Under the January 17, 2025 proposal (90 FR 6541), Schedules III through V would be covered by the basic Telemedicine Prescribing Registration, without the specialty limits DEA proposed for Schedule II. The prescriber would still need a State Telemedicine Registration for each patient state, a PDMP check before each prescription, and audio-video encounters. Proposed fees were $888 per three-year cycle for the special registration and $50 per state for each State Telemedicine Registration. None of it is final; a final rule went to OIRA on August 25, 2026, and the details are in our special registration explainer.

Which states restrict testosterone by telehealth?

A handful of state laws reach Schedule III directly. From the statutes we have read:

• Connecticut is the sharpest. Conn. Gen. Stat. § 19a-906(c) says no telehealth provider shall prescribe any Schedule I, II or III controlled substance through telehealth, except a Schedule II or III drug for medication-assisted treatment or to treat a psychiatric disability or substance use disorder, as amended by Public Act 25-168. Testosterone for hypogonadism does not fit the exception, so a Connecticut patient needs a different route.
• Alabama (Ala. Code § 34-24-704) requires a synchronous visit and at least one in-person encounter with the prescriber in the prior 12 months before any controlled substance is prescribed by telehealth.
• Louisiana Board of Medical Examiners rules (La. Admin. Code tit. 46, pt. XLV, § 7513) require an in-person visit within the past year before a controlled substance is prescribed by telemedicine, with limited exceptions.
• Colorado's out-of-state telehealth registration (C.R.S. § 12-30-124) does not let registrants prescribe any controlled substance. An out-of-state clinician needs a full Colorado license to prescribe testosterone there.

Most other states do not single out Schedule III, but nearly all require a state license or registration, a valid relationship and, in many, a state controlled substance registration. The state pages in our telehealth law index list the rule we found for each, with the citation.

What about state controlled substance registrations?

A DEA number is not the end of it. Jurisdictions including Connecticut, Delaware, Maryland, Louisiana, Alabama and the District of Columbia require their own controlled substance registration before a practitioner prescribes to patients there. For NPs, White Glove APRN keeps a state-by-state CSR and CDS list; physicians can start with White Glove IMLC's state controlled substance registration guide. Our sisters file these; we do not.

What does a defensible testosterone telehealth protocol include?

1. Baseline labs before the first prescription, drawn through a lab partner in the patient's state, and documented review of them.
2. A visit that could stand on its own. Real-time video, a history, a documented diagnosis and a discussion of risks and alternatives.
3. A PDMP check where the patient's state requires one for Schedule III; see PDMP checks for telehealth prescribers.
4. Six-month prescription cycles that line up with follow-up labs and visits.
5. A state block list. Connecticut out until counsel says otherwise, Colorado limited to fully licensed clinicians, Alabama and Louisiana gated on an in-person visit.
6. An in-person plan for January 2027 if DEA has not acted.

Our post on running a telehealth hormone therapy clinic covers pharmacy, lab and marketing questions. For the regulatory work, DEA Telemedicine Readiness ($1,450) maps every testosterone patient to a lawful pathway for 2027, and a 50-State Telehealth Matrix ($2,950) gives counsel the state-by-state prescribing rules. This is research for your counsel, not legal advice.